Abstract
Adjuvants can stimulate vaccine-induced immune responses and can contribute decisively to antigen dose sparing when vaccine antigen production is limited, as for example during a pandemic influenza outbreak. We earlier showed that GPI-0100, a semi-synthetic saponin derivative with amphiphilic structure, significantly stimulates the immunogenicity and protective efficacy of influenza subunit vaccine administered via a systemic route. Here, we evaluated the adjuvant effect of GPI-0100 on a virosomal influenza vaccine formulation. In contrast to influenza subunit vaccine adjuvanted with GPI-0100, virosomal vaccine supplemented with the same dose of GPI-0100 provided full protection of mice against infection at the extremely low antigen dose of 2 x 8 ng hemagglutinin. Overall, adjuvanted virosomes elicited higher antibody and T-cell responses than did adjuvanted subunit vaccine. The enhanced immunogenicity of the GPI-0100-adjuvanted virosomes, particularly at low antigen doses, is possibly due to a physical association of the amphiphilic adjuvant with the virosomal membrane. These results show that a combination of GPI-0100 and a virosomal influenza vaccine formulation is highly immunogenic and allows the use of very low antigen doses without compromising the protective potential of the vaccine.
Original language | English |
---|---|
Pages (from-to) | 47-55 |
Number of pages | 9 |
Journal | Medical microbiology and immunology |
Volume | 203 |
Issue number | 1 |
DOIs | |
Publication status | Published - Feb-2014 |
Keywords
- Influenza vaccine
- GPI-0100
- Subunit
- Virosome
- MEDIATED DELIVERY
- PROTEIN ANTIGENS
- IMMUNOGENICITY
- RESPONSES
- SUBUNIT
- SAFETY
- VIRUS
- METAANALYSIS
- PROTECTION
- INDUCTION